Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study

Urology

Volumn 48, Issue 2, 1996, Pages 234-239

  Deantoni, Edward P ^a   Crawford, E David ^b   Oesterling, Joseph E ^b   Ross, Colleen A ^b   Berger, E Roy ^b   McLeod, David G ^b   Staggers, Frank ^b   Stone, Nelson N ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ANTIGEN DETECTION; ARTICLE; ASIAN AMERICAN; CAUCASIAN; COMMUNITY CARE; ETHNIC GROUP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE;

EID: 0030219832     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00091-X     Document Type: Article

References (44)

1. 1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. 2. Cancer Facts and Figures - 1995. Atlanta: American Cancer Society, 1995.
3. 3. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
4. 4. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, and Edwards BK (Eds). SEER Cancer Statistics Review, 1973-1991: Tables and Graphs, National Cancer Institute. NIH Pub. No. 94-2789. Bethesda, MD, 1994, p 372.
5. 5. Rosen MA: Impact of prostate-specific antigen screening on the natural history of prostate cancer. Urology 46: 757-768, 1995.
6. 6. Kramer BS, Brown ML, Prorok PC, Potosky AL, and Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119: 914-923, 1993.
7. o or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. Urology 41: 3-8, 1993.
8. 8. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271: 368-374, 1994.
9. 9. Epstein JI, Carmichael MJ, Partin AW, and Walsh PC: Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 151: 1587-1592, 1994.
10. 10. Gann PH, Hennekens CH, and Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289-294, 1995.
11. 11. Carter HB, Pearson JD, Metter JE, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
12. 12. Carter HB, Pearson JD, Waclawiw Z, Metter EJ, Chan DW, Guess HA, and Walsh PC: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 45: 591-596, 1995.
13. 13. Scardino PT, Weaver R, and Hudson MA. Early detection of prostate cancer. Hum Pathol 23: 211-222, 1992.
14. 14. Ohori M, Wheeler TM, Kattan MW, Goto Y, and Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824, 1995.
15. 15. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, and Babaian R, for the Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cost-effective prostate cancer detection: reduction of low-yield biopsies. Cancer 74: 3146-3158, 1994.
16. 16. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42: 365-374, 1993.
17. 17. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
18. 18. Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays. Urology 45: 173-184, 1995.
19. 19. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
20. 20. Kalish J, Cooner WH, and Graham SD Jr: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43: 601-606, 1994.
21. 21. Carter HB, and Pearson JD: PSA velocity for the diagnosis of early prostate cancer: A new concept. Urol Clin North Am 20: 665-670, 1993.
22. 22. Lilja H: Significance of different molecular forms of serum PSA: the free, noncomplexed form of PSA versus that complexed to α1-antichymotrypsin. Urol Clin North Am 20: 681-686, 1993.
23. 23. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M-T, Cockett ATK, Abrahamsson P-A, and Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
24. 24. Luderer AA, Chen Y-T, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
25. 25. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
26. 26. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
27. 27. Babaian RJ, Miyashita H, Evans RB, and Ramirez E: The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 147: 837-840, 1992.
28. 28. Dalkin BL, Ahmann F, Southwick P, and Bottaccini MR: Derivation of normal prostate-specific antigen (PSA) level by age. J Urol 149: 413A, 1993.
29. 29. Collins GN, Lee RJ, McKelvie GB, Rogers AC, and Hehir M: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71: 445-450, 1993.
30. 30. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, and Ratliff TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 154: 407-413, 1995.
31. 31. Stone NN, DeAntoni EP, and Crawford ED: Screening for prostate cancer by digital rectal examination and prostate-specific antigen: results from prostate cancer awareness week, 1989-1992. Urology 44(suppl 6A): 18-25, 1994.
32. 32. El-Galley RES, Petros JA, Sanders WH, Keane TE, Galloway NTM, Cooner WH, and Graham SD Jr: Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma. Urology 46: 200-204, 1995.
33. 33. Ross RK, Shimizu H, Paganini-Hill A, Honda G, and Henderson BE: Case-control studies of prostate cancer in blacks and whites in southern California. J Natl Cancer Inst 78: 869-74, 1987.
34. 34. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, and Henderson B: Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 76: 45-48, 1986.
35. 35. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, and Henderson BE: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339: 887-889, 1992.
36. 36. Morton RA Jr: Racial differences in adenocarcinoma of the prostate in North American men. Urology 44: 637-645, 1994.
37. 37. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al: Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 87: 652-661, 1995.
38. 38. Gilliland FD, Becker TM, Key CR, and Samet JM: Contrasting trends of prostate cancer incidence and mortality in New Mexico's Hispanics, non-Hispanic whites, American Indians, and blacks. Cancer 73: 2192-2199, 1994.
39. 39. DeAntoni EP, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, Gambert SR, and Staggers F: Prostate cancer awareness week, 1992: a summary of key findings. Clin Invest Med 16: 448-457, 1993.
40. 40. DeAntoni EP, and Crawford ED: Prostate cancer awareness week: education, service and research in a community setting. Cancer 75(suppl):1874-1879, 1995.
41. 41. Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, et al: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152: 2037-2042, 1994.
42. 42. Speights VO Jr, Brawn PN, Foster DM, Spiekerman AM, Kuhl D, and Riggs MW: Evaluation of age-specific normal ranges for prostate-specific antigen. Urology 45: 454-458, 1995.
43. 43. Anderson JR, Strickland D, Crobin D, Byrnes JA, and Zweiback E: Age-specific reference ranges for serum prostate-specific antigen. Urology 46: 54-57, 1995.
44. 44. Meikle AW, Stephenson RA, McWhorter WP, Skolnick MH, and Middleton RG: Effects of age, sex steroids, and family relationships on volumes of prostate zones in men with and without prostate cancer. Prostate 26: 253-259, 1995.